Skip to main content
LIGAND PHARMACEUTICALS INC logo

LIGAND PHARMACEUTICALS INC — Investor Relations & Filings

Ticker · LGND ISIN · US53220K5048 LEI · 5493008K7TB0IKP37H79 US Financial and insurance activities
Open in API
Filings indexed 1,392 across all filing types
Latest filing 2025-02-27 Earnings Release
Country US United States of America
Listing US LGND

About LIGAND PHARMACEUTICALS INC

https://www.ligand.com/

Ligand Pharmaceuticals Incorporated is a biopharmaceutical company that functions as a capital and technology partner to the life sciences industry. The company's business model focuses on acquiring and developing royalty-generating assets by investing in the clinical development and commercialization of medicines. It manages a large, diverse portfolio of economic rights to partnered programs across therapeutic areas such as oncology, kidney disease, diabetes, and rare conditions. In addition to its royalty business, Ligand develops and licenses its proprietary technology platforms to a global network of biopharmaceutical partners. Its key technologies include Captisol®, a chemically modified cyclodextrin used to improve the solubility and stability of active pharmaceutical ingredients, and the NITRICIL™ platform.

Recent filings

Filing Released Lang Actions
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated February 27, 2025, reporting the issuance of a press release announcing financial results for the three and twelve months ended December 31, 2024. The text explicitly states that the press release is furnished as an exhibit and that the information is not deemed "filed" for purposes of Section 18 of the Exchange Act, indicating this is a current report announcing financial results rather than the full earnings report itself. The document length is 3644 characters, which is relatively short and consistent with a current report filing. The key section is Item 2.02 "Results of Operations and Financial Condition," which typically corresponds to an Earnings Release announcement. Therefore, this document is best classified as an Earnings Release (ER) announcement rather than a full Annual or Quarterly Report or Management Discussion. Confidence is high given the clear SEC form type and content.
2025-02-27 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content describes Ligand Pharmaceuticals entering into a material definitive agreement involving a purchase and sale agreement with Castle Creek Biosciences, including details about the transaction, warrants, and promissory notes. It also includes a press release as an exhibit. The document does not contain financial statements or detailed financial analysis but rather announces a significant financing and investment transaction. This fits the definition of a Capital/Financing Update (CAP) as it provides updates on company fundraising and capital structure changes. The document length is 8458 characters, which is sufficient to contain substantive information about the transaction rather than just a brief announcement. Therefore, the appropriate classification is CAP with high confidence.
2025-02-25 English
PRIMARY DOCUMENT
Director's Dealing
2025-02-20 English
PRIMARY DOCUMENT
Director's Dealing
2025-02-20 English
PRIMARY DOCUMENT
Director's Dealing
2025-02-20 English
Major Shareholding Notification 2025
Major Shareholding Notification
2025-02-14 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.